AI Article Synopsis
- A study was conducted with 49 children aged 1-12 years who took oseltamivir for 6 weeks to prevent influenza.
- Out of these, 17 children reported a total of 22 adverse events, with three likely linked to the medication (nausea or vomiting).
- No serious adverse events occurred, and the medication's tolerability was similar to data from shorter treatment studies.
Article Abstract
In an open-label study, 49 children aged 1-12 years received oseltamivir (30-75 mg once daily depending on bodyweight) for 6 weeks for influenza prophylaxis. Seventeen participants reported 22 adverse events (AEs); in three participants, AEs were considered probably drug related (nausea or vomiting). No serious AEs were reported. The tolerability profile was similar to pooled safety data from treatment studies (duration of 5 days) in children.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780728 | PMC |
| http://dx.doi.org/10.1111/j.1750-2659.2012.00367.x | DOI Listing |
Publication Analysis
Top Keywords
safety tolerability
4
tolerability 6-week
4
6-week course
4
course oseltamivir
4
oseltamivir prophylaxis
4
prophylaxis seasonal
4
seasonal influenza
4
influenza children
4
children open-label
4
open-label study
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!